# OSR Health Amends VXM01 License Agreement to Add $15 Million Convertible Note Option

- URL: https://stocks.freetheai.org/news/osr-health-amends-vxm01-license-agreement-to-add-15-million-convertible-note-9bf57f
- Published: 2026-10-16T13:23:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [OTC:OSRH](https://stocks.freetheai.org/symbols/OTC-OSRH)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

OSR Health, Inc. (OTC:OSRH) has updated its exclusive global licensing agreement for VXM01 with BCM Europe. Under Amendment No. 1, signed and effective on October 15, 2026, the company can choose an alternative settlement using a convertible note option worth up to $15 million. This arrangement allows funding to be drawn across four equal tranches of $3.75 million with set conversion prices near $2, $3, $4, and $5 per share, without price resets and subject to Nasdaq minimum price rules.

The modification aims to provide OSR Health with financial flexibility after receiving a delisting determination from Nasdaq. Counterparty BCM Europe must deliver a binding commitment from a purchaser, with each transaction closing at least 20 business days after election. If a transaction fails to complete within 10 business days after its planned target, the original equity settlement structure will be restored.

Investors should monitor whether OSR Health decides to exercise these convertible note tranches and whether BCM Europe fulfills its purchasing commitments within the set timelines. Additionally, market participants will watch how the company navigates its capital needs while trading over the counter following its removal from the Nasdaq exchange.

## Key points

- OSR Health amended its VXM01 global exclusive license agreement with BCM Europe on October 15, 2026.
- The amendment introduces a convertible note option allowing OSR Health to elect up to $15 million in funding.
- Financing is structured into four $3.75 million tranches with fixed conversion prices of roughly $2, $3, $4, and $5 per share.
- BCM Europe must provide binding purchaser commitments, with closing dates set at least 20 business days after election.
- The changes were made to secure capital flexibility following a Nasdaq delisting action.

## Questions and answers

### What is OSR Health's new convertible note option?

OSR Health added an option to its VXM01 license agreement allowing it to elect up to $15 million in convertible notes. The capital can be drawn in four $3.75 million tranches with fixed conversion prices around $2, $3, $4, and $5 per share.

### Why did OSR Health modify its agreement with BCM Europe?

The amendment was made to preserve financing flexibility and establish alternative settlement terms following a Nasdaq delisting determination.

### What happens if a convertible note tranche fails to close?

If a note purchase fails to close within 10 business days of the scheduled closing date, the agreement reinstates the original equity option.